Compare AEG & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEG | PEN |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 10.9B |
| IPO Year | N/A | 2015 |
| Metric | AEG | PEN |
|---|---|---|
| Price | $7.93 | $287.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $307.19 |
| AVG Volume (30 Days) | ★ 5.5M | 518.1K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 4.74% | N/A |
| EPS Growth | N/A | ★ 367.34 |
| EPS | 0.93 | ★ 4.14 |
| Revenue | ★ $15,344,685,849.00 | $1,333,798,000.00 |
| Revenue This Year | N/A | $15.52 |
| Revenue Next Year | $2.04 | $14.20 |
| P/E Ratio | ★ $8.41 | $69.93 |
| Revenue Growth | 2.83 | ★ 14.61 |
| 52 Week Low | $5.42 | $221.26 |
| 52 Week High | $8.15 | $310.00 |
| Indicator | AEG | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 61.18 | 61.83 |
| Support Level | $7.88 | $276.01 |
| Resistance Level | $8.02 | $298.69 |
| Average True Range (ATR) | 0.11 | 7.71 |
| MACD | 0.04 | 0.73 |
| Stochastic Oscillator | 86.67 | 53.70 |
Aegon is a life insurance and long-term savings business listed in the Netherlands. It listed on the Amsterdam Stock Exchange in the 1980s and now has mature operations in the United States, the United Kingdom, and four growth markets of Brazil, China, Portugal, and Spain. Over recent years, Aegon has been moving through an extensive transformation program where management has sought to divest noncore operations and improve the risk profile of the business. Financial assets are the parts of the group that are now being run off. Aegon is looking to cycle out of capital-consumptive and volatile-earnings products and recycle funds into capital-light and more predictable strategic businesses.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.